Loss of function of the PTEN tumour suppressor, resulting in dysregulated activation of the
phosphoinositide 3-kinase (PI3K) signalling network, is recognized as one of the most …

Although the prognosis of patients with localized prostate cancer is good after surgery, with
a favorable response to androgen deprivation therapy, about one third of them invariably …

Background Despite significant advances in molecular characterization and therapeutic
targeting of advanced prostate cancer, it remains the second most common cause of cancer …

Genomic aberrations of the PTEN tumour suppressor gene are among the most common in
prostate cancer. Inactivation of PTEN by deletion or mutation is identified in∼ 20% of …

Loss of the tumor suppressor phosphatase and tensin homologue deleted on chromosome
10 (PTEN), which negatively regulates the PI3K–AKT–mTOR pathway, is strongly linked to …

PTEN (phosphatase and tensin homologue deleted on chromosome-10), a dual specificity
phosphatase, is a tumor suppressor gene whose inactivation has been associated with …

PTEN activity is often lost in prostate cancer. We show that the tyrosine kinase PTK6 (BRK)
is a PTEN substrate. Phosphorylation of PTK6 tyrosine 342 (PY342) promotes activation …

The tumor suppressor PTEN was originally identified as a negative regulator of the
phosphoinositide 3-kinase (PI3K) signaling, a main regulator of cell growth, metabolism and …

PTEN is a phosphatase which metabolises PIP 3, the lipid product of PI 3-Kinase, directly
opposing the activation of the oncogenic PI3K/AKT/mTOR signalling network. Accordingly …

Purpose PTEN is an essential tumour suppressor gene which encodes a phosphatase
protein that antagonises the PI3K/Akt/mTOR antiapoptotic pathway. Impairment of this …